Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
SLN logo SLN
Upturn stock ratingUpturn stock rating
SLN logo

Silence Therapeutics PLC (SLN)

Upturn stock ratingUpturn stock rating
$4.73
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

09/15/2025: SLN (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

7 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $33.94

1 Year Target Price $33.94

Analysts Price Target For last 52 week
$33.94 Target price
52w Low $1.97
Current$4.73
52w High $20.48

Analysis of Past Performance

Type Stock
Historic Profit 134.5%
Avg. Invested days 34
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 5.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 09/15/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 226.72M USD
Price to earnings Ratio -
1Y Target Price 33.94
Price to earnings Ratio -
1Y Target Price 33.94
Volume (30-day avg) 7
Beta 1.38
52 Weeks Range 1.97 - 20.48
Updated Date 09/15/2025
52 Weeks Range 1.97 - 20.48
Updated Date 09/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.68

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -291.24%
Operating Margin (TTM) -9048.21%

Management Effectiveness

Return on Assets (TTM) -22.25%
Return on Equity (TTM) -66.96%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 90248956
Price to Sales(TTM) 8.34
Enterprise Value 90248956
Price to Sales(TTM) 8.34
Enterprise Value to Revenue 3.32
Enterprise Value to EBITDA -5.78
Shares Outstanding 47233900
Shares Floating 74747724
Shares Outstanding 47233900
Shares Floating 74747724
Percent Insiders 24.38
Percent Institutions 44.31

ai summary icon Upturn AI SWOT

Silence Therapeutics PLC

stock logo

Company Overview

overview logo History and Background

Silence Therapeutics, founded in 1994, pioneered siRNA therapeutics. Initially focused on gene silencing technology, it has evolved into a clinical-stage biotechnology company developing next-generation siRNA therapeutics for various diseases.

business area logo Core Business Areas

  • siRNA Therapeutics Development: Develops and commercializes siRNA-based drugs targeting specific genes to treat diseases.

leadership logo Leadership and Structure

The leadership team consists of experienced executives in the biotechnology and pharmaceutical industries. The organizational structure includes research and development, clinical operations, and commercialization functions.

Top Products and Market Share

overview logo Key Offerings

  • SLN360: A siRNA therapeutic targeting lipoprotein(a) (Lp(a)) for cardiovascular disease. Currently in clinical trials. Competitors include Novartis and Amgen in the Lp(a) reducing space. Market share data unavailable as product is not yet commercialized. Focus is reducing Lp(a) levels which in turn can reduce cardiovascular risks and incidents.
  • SLN124: A siRNA therapeutic targeting TMPRSS6 for iron overload disorders. Currently in clinical trials. Competitors are companies developing treatments for anemia and iron overload, such as Protagonist Therapeutics and Disc Medicine. Market share data unavailable as product is not yet commercialized. Focus is hepcidin modulation to improve erythropoiesis.

Market Dynamics

industry overview logo Industry Overview

The RNAi therapeutics market is growing rapidly, driven by technological advancements and increasing investment in drug development. The market is becoming increasingly competitive with both large pharmaceutical companies and smaller biotech firms.

Positioning

Silence Therapeutics is a specialized biotechnology company with expertise in siRNA technology. Its competitive advantage lies in its proprietary mRNAiGOLD platform and its focus on developing highly targeted therapeutics.

Total Addressable Market (TAM)

The total addressable market for siRNA therapeutics is estimated to reach billions of dollars in the coming years. Silence Therapeutics aims to capture a significant share of this market by targeting specific disease areas with high unmet needs.

Upturn SWOT Analysis

Strengths

  • Proprietary mRNAiGOLD platform
  • Strong intellectual property portfolio
  • Experienced management team
  • Clinical-stage pipeline

Weaknesses

  • Limited financial resources compared to larger pharmaceutical companies
  • Dependence on successful clinical trial outcomes
  • Reliance on partnerships for commercialization

Opportunities

  • Expanding into new therapeutic areas
  • Securing partnerships with larger pharmaceutical companies
  • Advancing pipeline candidates through clinical development
  • Growing demand for RNAi therapeutics

Threats

  • Competition from other RNAi therapeutics companies
  • Regulatory hurdles
  • Clinical trial failures
  • Patent disputes

Competitors and Market Share

competitor logo Key Competitors

  • ALNY
  • VIR
  • IONS

Competitive Landscape

Silence Therapeutics faces competition from established RNAi therapeutics companies. Its competitive advantage lies in its mRNAiGOLD platform, but its smaller size and limited resources compared to larger companies present challenges.

Growth Trajectory and Initiatives

Historical Growth: Silence Therapeutics' historical growth has been driven by its advancements in siRNA technology and progression of its clinical pipeline.

Future Projections: Future growth is projected to be driven by successful clinical trial outcomes, regulatory approvals, and commercialization of its siRNA therapeutics.

Recent Initiatives: Recent initiatives include advancing SLN360 and SLN124 through clinical trials, expanding its pipeline through internal research and development, and seeking strategic partnerships.

Summary

Silence Therapeutics is a biotech company with a promising siRNA platform. Clinical trial successes are vital for future growth. Competition in the RNAi therapeutics market poses challenges. Strategic partnerships are crucial for commercialization and expanding its market reach. Financial stability is essential for continued advancement.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Silence Therapeutics PLC website
  • SEC filings
  • Analyst reports
  • Industry publications

Disclaimers:

This analysis is based on available information and is not financial advice. Market data and projections are subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Silence Therapeutics PLC

Exchange NASDAQ
Headquaters -
IPO Launch date 2020-09-08
President, CEO & Executive Director Mr. Craig A. Tooman M.B.A.
Sector Healthcare
Industry Biotechnology
Full time employees 116
Full time employees 116

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trial for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. Silence Therapeutics plc has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.